Concurrent administration of donepezil HCl and ketoconazole: Assessment of pharmacokinetic changes following single and multiple doses

British Journal of Clinical Pharmacology, Supplement

Volumn 46, Issue 1, 1998, Pages 30-34

  Tiseo, P J ^a   Perdomo, C A ^a   Friedhoff, L T ^a  

^a EISAI INC   (United States)

Author keywords

Acctylcholinesterase inhibitor; Donepezil; Drug drug interaction; Ketoconazole

Indexed keywords

ANTIFUNGAL AGENT; CHOLINESTERASE INHIBITOR; CYTOCHROME P450 3A4; DEBRISOQUINE 4 HYDROXYLASE; DONEPEZIL; KETOCONAZOLE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0032420331     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.0460s1030.x     Document Type: Article

References (21)

1. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-417.
2. Giacobini E. Pharmacotherapy of Alzheimer's disease: new drugs and novel strategies. Prog Brain Res 1993; 98: 447-454.
3. Doraiswamy PM. Current cholinergic therapy for symptoms of Alzheimer's disease. Primary Psychiatry 1996; 3: 56-68.
4. Yamanishi Y, Ogura H, Kosasa T, Araki S, Sawa Y, Yamatsu K. Inhibitory action of donepezil, a novel acetylcholinesterase inhibitor, on cholinesterase. Comparison with other inhibitors. In Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, Volume 2, eds Nagatsu T, Fisher A, Yoshida M. New York: Plenum Press, 1990: 409-413.
5. Cardozo MG, Iimura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ. QSAR analysis of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem 1992; 35: 584-589.
6. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds. Biorg Med Chem Lett 1992; 2: 871-876.
7. Pang YP, Kozikowski AP. Prediction of the binding site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine in acetylcholinesterase by docking studies with the SYSDOC program. J Comput Aided Mol Design 1994; 8: 683-693.
8. Nochi S, Asakawa N, Sato T. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020). Biol Pharm 1995; 18: 1145-1147.
9. Rogers SL, Yamanishi Y, Yamatsu K. E2020 - the pharmacology of a piperidine cholinesterase inhibitor. In Cholinergic Basis for Alzheimer Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1991: 314-320.
10. Rogers SL, Friedhoff LT, the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303.
11. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
12. Rogers SL, Doody RS, Mohs R, Fnedhoff LT, the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158: 1021-1031.
13. Mihara M, Ohnishi A, Tomono Y et al. Pharmacokinetics of E2020 - a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993; 31: 223-229.
14. Reynolds JEF (ed). Martindale, The Extra Pharmacopoeia, 31st edn. London: The Pharmaceutical Press, 1996: 410-411.
15. Bennett JE. Antimicrobial agents: antifungal agents. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, eds Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. New York: McGraw-Hill, 1996: 1175-1190.
16. Babe KS, Serafin WE. Histamine, bradykinin, and their antagonists. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn, eds Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. New York: McGraw-Hill, 1996: 581-600.
17. Khosla S, Wolfson JS, Demerjian Z, Godine JE. Adrenal crisis in the setting of high-dose ketoconazole therapy. Arch Intern Med 1989; 149: 802-804.
18. Ament PW, Paterson A. Drug interactions with the nonsedating antihistamines. Am Fam Physician 1997; 56: 223-231.
19. Sadowski DC. Drug interactions with antacids. Mechanisms and clinical significance. Drug Saf 1994; 11: 395-407.
20. Lee JW, Rogers SL, Friedhoff LT, Stiles MR, Cooper NM. Validation and application of an HPLC method for the determination of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine HCl (E2020) in human plasma. Pharm Res 1992; 9: S350.
21. Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998; 46 (Suppl. 1): 13-18.